File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog

TitleResponsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog
Authors
KeywordsHypercalcemia
Neuroblastoma
Retinoblastoma
Tumor inhibition
Vitamin D analog
Issue Date2005
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/jsbmb
Citation
Journal Of Steroid Biochemistry And Molecular Biology, 2005, v. 97 n. 1-2, p. 165-172 How to Cite?
AbstractObjectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB. © 2005 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/92829
ISSN
2015 Impact Factor: 3.985
2015 SCImago Journal Rankings: 1.425
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAlbert, DMen_HK
dc.contributor.authorPlum, LAen_HK
dc.contributor.authorYang, Wen_HK
dc.contributor.authorMarcet, Men_HK
dc.contributor.authorLindstrom, MJen_HK
dc.contributor.authorClagettDame, Men_HK
dc.contributor.authorDeLuca, HFen_HK
dc.date.accessioned2010-09-17T10:58:36Z-
dc.date.available2010-09-17T10:58:36Z-
dc.date.issued2005en_HK
dc.identifier.citationJournal Of Steroid Biochemistry And Molecular Biology, 2005, v. 97 n. 1-2, p. 165-172en_HK
dc.identifier.issn0960-0760en_HK
dc.identifier.urihttp://hdl.handle.net/10722/92829-
dc.description.abstractObjectives: To investigate the effectiveness of 2-methylene-19-nor-(20S)- 1α-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB). Methods: For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic β-luteinizing hormone-large T antigen (LHβ-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed. Results: In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival. Conclusions: In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality. Clinical relevance: 2MbisP should be considered for use in clinical trials of RB and NB. © 2005 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/jsbmben_HK
dc.relation.ispartofJournal of Steroid Biochemistry and Molecular Biologyen_HK
dc.subjectHypercalcemiaen_HK
dc.subjectNeuroblastomaen_HK
dc.subjectRetinoblastomaen_HK
dc.subjectTumor inhibitionen_HK
dc.subjectVitamin D analogen_HK
dc.titleResponsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analogen_HK
dc.typeArticleen_HK
dc.identifier.emailMarcet, M: marcet@hku.hken_HK
dc.identifier.authorityMarcet, M=rp01363en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jsbmb.2005.06.019en_HK
dc.identifier.pmid16055326-
dc.identifier.scopuseid_2-s2.0-27544478276en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27544478276&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume97en_HK
dc.identifier.issue1-2en_HK
dc.identifier.spage165en_HK
dc.identifier.epage172en_HK
dc.identifier.isiWOS:000233543100021-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAlbert, DM=36044032300en_HK
dc.identifier.scopusauthoridPlum, LA=6603816048en_HK
dc.identifier.scopusauthoridYang, W=19838753600en_HK
dc.identifier.scopusauthoridMarcet, M=8891087900en_HK
dc.identifier.scopusauthoridLindstrom, MJ=34571495000en_HK
dc.identifier.scopusauthoridClagettDame, M=7004554927en_HK
dc.identifier.scopusauthoridDeLuca, HF=7202098766en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats